Zacks.com featured highlights include Stryker, NVIDIA, ResMed and Ralph Lauren

20.10.25 17:46 Uhr

Werte in diesem Artikel
Aktien

156,20 EUR -0,96 EUR -0,61%

22,80 EUR 0,40 EUR 1,79%

326,30 EUR 5,70 EUR 1,78%

Indizes

PKT PKT

46.924,7 PKT 218,2 PKT 0,47%

25.127,1 PKT -13,9 PKT -0,06%

22.953,7 PKT -36,9 PKT -0,16%

6.735,4 PKT 0,2 PKT 0,00%

For Immediate ReleaseChicago, IL – October 20, 2025 – Stocks in this week’s article are Stryker SYK, NVIDIA NVDA, ResMed RMD and Ralph Lauren RL.4 GARP Stocks Investors Can Scoop Up for Maximum ReturnsGrowth at a reasonable price, or GARP, is an excellent strategy to earn quick investment profits. The GARP approach helps identify stocks priced below the market or any suitable target determined by a fundamental analysis.The strategy helps investors gain exposure to stocks with impressive prospects and trading at a discount. GARP stocks have solid prospects in terms of cash flow, revenues, earnings per share (EPS) and other metrics.A portfolio based on the GARP strategy comprises stocks that offer the best value and growth investment. Stryker, NVIDIA, ResMed and Ralph Lauren are some promising GARP stocks.GARP Metrics: Mix of Growth & Value MetricsThe GARP strategy offers ideal investment options, utilizing the best value and growth investing features. Investors adopting the GARP approach prefer stocks priced below the market or any reasonable target determined by fundamental analysis. The stocks have solid prospects based on cash flow, revenues, EPS, etc.Growth MetricsA strong earnings growth history and impressive earnings prospects are the primary concepts that GARP investors borrow from the growth investing strategy. However, instead of super-normal rates, pursuing stocks with a more stable and reasonable growth rate is a tactic of GARP investors. The GARP strategy considers growth rates between 10% and 20% ideal.Another metric considered by growth and GARP investors is return on equity (ROE). GARP investors look for strong and higher ROE than the industry average to identify superior stocks. Moreover, stocks with a positive cash flow find precedence under the GARP plan.Value MetricsGARP investing prioritizes one of the popular value metrics, the price-to-earnings (P/E) ratio. The investing style picks stocks with higher P/E ratios than value investors, but it avoids companies with extremely high P/E ratios. The price-to-book value (P/B) ratio is also taken into consideration.Using the GARP principle, we have run a screen to identify stocks that should offer solid returns in the near term.Here are four out of the 12 stocks that made it through the screen. Each of the four stocks carries a Zacks Rank #2.Stryker's international business remains a long-term growth lever, with double-digit gains in Asia-Pacific and Latin America. The company's innovation pipeline remains strong, with developments across orthopaedics, trauma, extremities, and endoscopy. Hospitals are actively refreshing capital equipment and investing in advanced surgical technologies, driving greater utilization across Stryker's broad portfolio. Neurotechnology's strong growth is fueled by robust demand in craniomaxillofacial and stroke care products. Collectively, these segments provide stability and balance to Stryker's overall growth trajectory.The Mako platform is steadily broadening its procedural reach, while upcoming launches in sports medicine and next-generation endoscopy are set to reinforce the company's competitive positioning. Management noted that Mako procedures surpassed the 2-million milestone in the second quarter, with international markets contributing significantly as hospitals expand their robotic-assisted surgery capabilities.Rising Mako placements are boosting implant volumes and embedding robotics more deeply into orthopedic care. These dynamics reinforce Stryker's technology leadership and highlight the near-term momentum of robotics in enhancing surgical efficiency and patient outcomes.The stock has returned 2.6% in the year-to-date period. It has a trailing four-quarter earnings surprise of 3.3%, on average. The Zacks Consensus Estimate for SYK's 2025 earnings has moved 0.1% north to $13.5 per share over the past 60 days.NVIDIA is benefiting from the strong growth of AI and high-performance accelerated computing. The growing demand for generative AI and large language models using graphics processing units (GPUs) based on NVIDIA's Hopper and Blackwell architectures is aiding data center revenues. The company's networking business, including NVLink and Spectrum-X, is also contributing to growth by enabling faster and more efficient data movement within AI clusters. These add-ons make NVIDIA's full-stack approach more appealing to enterprises and governments building AI infrastructure.The continued ramp-up of Ada RTX GPU workstations in the ProViz end market, following the normalization of channel inventory, is acting as a tailwind. Collaborations with more than 320 automakers and tier-one suppliers are likely to advance its presence in the autonomous vehicle space. We expect NVIDIA's revenues to witness a CAGR of 31% through fiscal 2026-2028.The stock has returned 35.4% in the year-to-date period. It has a trailing four-quarter earnings surprise of 3.56%, on average. The Zacks Consensus Estimate for NVDA's fiscal 2026 earnings has moved 4.7% north to $4.45 per share over the past 60 days.ResMed's continued product development is driving growth within this business globally. The company's AirFit F40 is performing extremely well in the U.S. market. It also features AirTouch N30i, the world's first unique fabric-based patient interface, which was launched in select markets. Early feedback for AirTouch N30i was positive.ResMed's increased device sales continue to drive overall revenue growth, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices to support strong underlying global demand. In the fourth quarter of fiscal 2025, the company successfully maintained its market leadership, banking on its two AirSense platforms.This stock has returned 18.1% in the year-to-date period. It has a trailing four-quarter earnings surprise of 4.53%, on average. The Zacks Consensus Estimate for RMD's fiscal 2026 earnings has remained steady at $10.87 per share over the past 60 days.Ralph Lauren is benefiting from investor confidence in its robust brand equity, successful execution of its strategic transformation and consistent performance across geographies and channels. RL's strong pricing power, margin expansion, disciplined inventory and real estate management are key growth drivers for the long term.Innovations like predictive buying and AI-enabled planning are improving inventory efficiency and responsiveness. Across platforms owned, wholesale and social, Ralph Lauren is not just keeping pace with digital trends but actively shaping them, creating immersive, emotionally resonant brand experiences that fuel both consumer loyalty and higher-margin sales.Ralph Lauren is also making smart investments in prime real estate to future-proof its presence, such as acquiring its Polo flagship in SoHo and aligning with a broader DTC-led growth strategy that continues to strengthen profitability.The stock has returned 39.9% in the year-to-date period. It has a trailing four-quarter earnings surprise of 8.49%, on average. The Zacks Consensus Estimate for RL's fiscal 2026 earnings has moved north by 0.2% to $14.93 per share over the past 60 days.You can get the remaining stocks on this list by signing up now for a 2-week free trial to the Research Wizard stock picking and backtesting software. You can also create your own strategies and test them first before making investments.The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in and see what gems come out.Click here to sign up for a free trial of the Research Wizard today.For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2771220/4-garp-stocks-that-investors-can-scoop-up-for-maximum-returnsDisclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.About Screen of the WeekZacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.Follow us on Twitter:  https://www.twitter.com/zacksresearchJoin us on Facebook:  https://www.facebook.com/ZacksInvestmentResearchZacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.Contact: Jim GiaquintoCompany: Zacks.comPhone: 312-265-9268Email: pr@zacks.comVisit: https://www.zacks.com/Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Ralph Lauren Corporation (RL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: NVIDIA und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf NVIDIA

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf NVIDIA

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu NVIDIA Corp.

Wer­bung

Analysen zu NVIDIA Corp.

DatumRatingAnalyst
29.09.2025NVIDIA BuyJefferies & Company Inc.
23.09.2025NVIDIA BuyUBS AG
23.09.2025NVIDIA OutperformBernstein Research
19.09.2025NVIDIA OverweightJP Morgan Chase & Co.
12.09.2025NVIDIA BuyJefferies & Company Inc.
DatumRatingAnalyst
29.09.2025NVIDIA BuyJefferies & Company Inc.
23.09.2025NVIDIA BuyUBS AG
23.09.2025NVIDIA OutperformBernstein Research
19.09.2025NVIDIA OverweightJP Morgan Chase & Co.
12.09.2025NVIDIA BuyJefferies & Company Inc.
DatumRatingAnalyst
20.08.2025NVIDIA HoldDeutsche Bank AG
10.01.2025NVIDIA HoldDeutsche Bank AG
21.11.2024NVIDIA HaltenDZ BANK
21.11.2024NVIDIA HoldDeutsche Bank AG
29.08.2024NVIDIA HoldDeutsche Bank AG
DatumRatingAnalyst
04.04.2017NVIDIA UnderweightPacific Crest Securities Inc.
24.02.2017NVIDIA UnderperformBMO Capital Markets
23.02.2017NVIDIA ReduceInstinet
14.01.2016NVIDIA UnderweightBarclays Capital
26.07.2011NVIDIA underperformNeedham & Company, LLC

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für NVIDIA Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen